Full-Time

Principal EP Mapping Specialist

Posted on 1/23/2025

Medtronic

Medtronic

10,001+ employees

Develops and manufactures medical devices and therapies

Compensation Overview

$150k - $155kAnnually

+ Sales Incentive Plan

Senior, Expert

Indianapolis, IN, USA

Category
Healthcare Administration & Support
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • High school diploma PLUS a minimum of 10 years of work experience in cardiac mapping and navigation.
  • OR Associate degree PLUS a minimum of 8 years of work experience in cardiac mapping and navigation.
  • OR Bachelor degree PLUS a minimum of 6 years of work experience in cardiac mapping and navigation.
Responsibilities
  • Provide clinical and technical support and training to physicians and staff on the EP mapping and navigation system and all CAS products.
  • Educate and train physicians, hospital personnel and office staff on technical matters relating to CAS products and related procedures.
  • Promote the safe and effective use of Medtronic CAS products and related procedures.
  • Understand and support national, regional and territory sales objectives to achieve or exceed sales goals within all CAS products.
  • Develop and cultivate customer relationships resulting in incremental business.
  • Work in partnership with Account Manager, Regional Manager and Area Directors to identify potential sales opportunities.
  • Collaborate and strategize with local sales team to conduct customer training for mapping and other CA Solutions products.
  • Collaborate and communicate with the sales and clinical teams in the region.
  • Serves as an effective Medtronic CAS representative to physicians and support staff regarding Medtronic CAS products, service and support.
  • Serve as a regional champion to share your experience and influence others to be proficient in the mapping technology.
Desired Qualifications
  • B.A./B.S. Degree in nursing, cardiovascular, life sciences, or technical discipline with minimum of four years work experience in cardiac field, hospital/clinic or sales.
  • Proven track record with technical training assignments.
  • Experience in the cardiac catheter ablation field, EP lab, in a hospital/clinic or EP medical sales providing technical / clinical support.
  • Ability to travel more than 25% of the time.

Medtronic provides medical technology, services, and solutions to improve patient care. The company develops a variety of medical devices, such as pacemakers, insulin pumps, surgical tools, and neurostimulation devices, which help diagnose, prevent, and treat chronic diseases. These products are used by hospitals and healthcare professionals around the world. Medtronic stands out from competitors by not only focusing on product development but also offering training, patient management programs, and technical support to healthcare providers. The goal of Medtronic is to enhance patient outcomes and lower healthcare costs through comprehensive solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Philips enhances market presence in emerging markets like India.
  • Consistent dividend increases over 47 years attract investors and enhance shareholder value.
  • Involvement in CRT 2025 conference may lead to new collaborations and innovations.

What critics are saying

  • Increased competition from emerging markets may impact Medtronic's market share.
  • Global semiconductor shortage could delay Medtronic's supply chain and product availability.
  • Rising regulatory scrutiny in the EU may lead to higher compliance costs for Medtronic.

What makes Medtronic unique

  • Medtronic leads in cardiovascular innovations with successful SMART trial outcomes for Evolut TAVR.
  • The company offers comprehensive healthcare solutions, including training and patient management programs.
  • Medtronic's 10-year initiative aims to propel 1M low-income students into health tech careers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Company News

Medical Device Network
Mar 10th, 2025
Medtronic announces two-year trial outcomes of Evolut TAVR

Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial's two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) and small aortic annulus.

DiCardiology
Mar 10th, 2025
Medtronic Presents New Data, Clinical Milestones at CRT 2025

Medtronic presents new data, clinical milestones at CRT 2025.

PR Newswire
Mar 9th, 2025
Smart Trial Two-Year Data Continues To Demonstrate Superior Valve Performance For Evolut Tavr™ System In Small Annulus Patients

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to primarily enroll women using the two most widely used global TAVR devicesGALWAY, Ireland and WASHINGTON, March 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior valve performance as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut™ TAVR compared to SAPIEN™. The late-breaking science was presented at the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C."Valve performance is critical for all patients, but the impact of poor valve performance is magnified in patients with a small aortic annulus, who are at risk of receiving a valve that is not adequate for their cardiac requirements," said Howard C. Herrmann, M.D., Perelman School of Medicine at the University of Pennsylvania, and lead investigator of the trial. "The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite clinical outcomes at this early stage, valve performance provides important data that operators can use to inform and personalize treatment decisions to enhance patient outcomes."The SMART two-year data demonstrated that Evolut TAVR continues to show significantly less BVD, which can be a predictor of adverse outcomes1, compared to SAPIEN TAVR

PR Newswire
Mar 6th, 2025
Medtronic Announces Cash Dividend For Fourth Quarter Of Fiscal Year 2025

GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the SP 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions

PR Newswire
Mar 4th, 2025
Jumpstart Ventures Announces First Close For Next Fund Iii

CLEVELAND, Ohio, March 4, 2025 /PRNewswire/ -- JumpStart Ventures has achieved the successful first close of NEXT Fund III, raising nearly $25 million toward its $50 million target. NEXT Fund III is supported by the State Small Business Credit Initiative (SSBCI) Ohio, institutional and private investors and reinforces JumpStart Ventures' commitment to providing tech founders with the capital they need to scale their startups.NEXT Fund III will invest in Seed and Series A startups and build upon JumpStart Ventures' two decades of experience supporting high-growth startups with risk capital while generating top returns for their investment partners.NEXT Fund III is JumpStart Ventures' third fund under its NEXT model and its eighth venture capital fund overall. With this first close, JumpStart Ventures is positioned to continue its momentum of funding high-growth startups."This close represents a significant step forward in supporting our region's most ambitious founders," said Hardik Desai, Managing Partner of JumpStart Ventures. "With the backing of our committed partners, we are focused on providing the capital and resources needed to help founders scale their businesses and bring groundbreaking technologies to market."JumpStart Ventures' portfolio has brought much excitement to the region's venture capital ecosystem in recent years, as demonstrated by the growth of several venture-backed startups like Abre, Centerline Biomedical, OnStation, Cleveland Diagnostics, Orthobrain, Axuall and Onshift. 30+ portfolio companies like CoverMyMeds, Able Software, Wireless Environment, CardioInsight, and Vizzle have been acquired generating significant returns for the investors.JumpStart Ventures manages four unique investment funds to drive startup growth, pairing stage-appropriate capital with deep connections and partnerships. As one of Ohio's most active early-stage investors, the organization's investment activities have generated top quartile investment returns via nationally recognized exits and fundraises

INACTIVE